Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

ERS Congress 2024

Keep up to date on the latest news from the annual European Respiratory Society conference.
ADVANCED SEARCH
Log in
Top
Drugs & Aging
Published in:

27-07-2024 | Hyperuricemia and Gout | Review Article

Managing Gout in Patients with Metabolic Syndrome

Authors: Esther Ebstein, Sébastien Ottaviani

Published in: Drugs & Aging | Issue 8/2024

Login to get access

Abstract

Gout is characterized by monosodium urate (MSU) crystal deposition secondary to hyperuricemia. Gout is associated with metabolic syndrome (MetS) and its related comorbid conditions such as cardiovascular disease (CVD). Major advances have been made in the comprehension of the link between MetS and gout. Despite observational studies suggesting an association between MetS-related conditions and hyperuricemia, there is no proof of causality. Most studies using Mendelian randomization did not find hyperuricemia as a causal factor for MetS-related conditions. In contrast, these conditions were found associated with hyperuricemia, which suggests a reverse causality. Among patients with gout, this high CVD risk profile implies the need for systematic screening for MetS-related conditions. Most international guidelines recommend systematic screening for and care of CVD and related risk factors in patients with gout. Some anti-hypertensive agents, such as losartan and calcium channel blockers, are able to decrease serum urate (SU) levels. However, there are potential interactions between gout management therapies and the treatment of metabolic diseases. Some data suggest that anti-inflammatory drugs used for gout flare treatment, such as colchicine or canakinumab, might have benefits for CVD. Regarding the impact of urate-lowering therapies on CVD risk, recent studies found a similar CVD safety profile for allopurinol and febuxostat. Finally, sodium-glucose cotransporter-2 inhibitors are promising for gout because of their ability to decrease SU levels and risk of recurrent flares. In this review, we focus on the clinical challenge of managing MetS in patients with gout, particularly older patients with co-medications.
Literature
1.
2.
Bursill D, Taylor WJ, Terkeltaub R, Abhishek A, So AK, Vargas-Santos AB, et al. Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout. Ann Rheum Dis. 2019;78(11):1592–600.PubMedCrossRef
3.
FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, et al. 2020 American College of Rheumatology guideline for the management of Gout. Arthritis Rheumatol. 2020;72(6):879–95.PubMedCrossRef
4.
Mandl P, D’Agostino MA, Navarro-Compan V, Gessl I, Sakellariou G, Abhishek A, et al. 2023 EULAR recommendations on imaging in diagnosis and management of crystal-induced arthropathies in clinical practice. Ann Rheum Dis. 2024;83(6):752–9.PubMedCrossRef
5.
Pascart T, Budzik JF. Dual-energy computed tomography in crystalline arthritis: knowns and unknowns. Curr Opin Rheumatol. 2022;34(2):103–10.PubMedCrossRef
6.
Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castaneda J, et al. 2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout. Ann Rheum Dis. 2020;79(1):31–8.PubMedCrossRef
7.
Leask MP, Merriman TR. The genetic basis of urate control and gout: Insights into molecular pathogenesis from follow-up study of genome-wide association study loci. Best Pract Res Clin Rheumatol. 2021;35(4): 101721.PubMedCrossRef
8.
Kuo CF, Grainge MJ, Zhang W, Doherty M. Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol. 2015;11(11):649–62.PubMedCrossRef
9.
Chen-Xu M, Yokose C, Rai SK, Pillinger MH, Choi HK. Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: the National Health and Nutrition Examination Survey, 2007–2016. Arthritis Rheumatol. 2019;71(6):991–9.PubMedPubMedCentralCrossRef
10.
Bardin T, Bouee S, Clerson P, Chales G, Flipo RM, Liote F, et al. Prevalence of Gout in the adult population of France. Arthritis Care Res (Hoboken). 2016;68(2):261–6.PubMedCrossRef
11.
Bardin T, Magnat E, Clerson P, Richette P, Rouchon B. Epidemiology of gout and hyperuricemia in New Caledonia. Joint Bone Spine. 2022;89(2): 105286.PubMedCrossRef
12.
13.
Pascart T, Wasik KA, Preda C, Chune V, Torterat J, Prud’homme N, et al. The gout epidemic in French Polynesia: a modelling study of data from the Ma’i u’u epidemiological survey. Lancet Glob Health. 2024;12(4):e685–96.PubMedCrossRef
14.
Xia Y, Wu Q, Wang H, Zhang S, Jiang Y, Gong T, et al. Global, regional and national burden of gout, 1990–2017: a systematic analysis of the Global Burden of Disease Study. Rheumatology (Oxford). 2020;59(7):1529–38.PubMedCrossRef
15.
Choi HK, Ford ES, Li C, Curhan G. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2007;57(1):109–15.PubMedCrossRef
16.
Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C, American Heart A, et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109(3):433–8.PubMedCrossRef
17.
Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, et al. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation. 2017;135(10):e146–603.PubMedPubMedCentralCrossRef
18.
19.
Wiley JF, Carrington MJ. A metabolic syndrome severity score: a tool to quantify cardio-metabolic risk factors. Prev Med. 2016;88:189–95.PubMedCrossRef
20.
Jung JH, Song GG, Ji JD, Lee YH, Kim JH, Seo YH, et al. Metabolic syndrome: prevalence and risk factors in Korean gout patients. Korean J Intern Med. 2018;33(4):815–22.PubMedCrossRef
21.
Schlesinger N, Elsaid MI, Rustgi VK. The relationship between metabolic syndrome severity and the risk of mortality in gout patients: a population-based study. Clin Exp Rheumatol. 2022;40(3):631–3.PubMedCrossRef
22.
Andres M. Gout and Cardiovascular Disease: Mechanisms, Risk Estimations, and the Impact of Therapies. Gout Urate Cryst Depos Dis. 2023;1(3):152–66.CrossRef
23.
Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation. 2007;116(8):894–900.PubMedCrossRef
24.
Ferguson LD, Molenberghs G, Verbeke G, Rahimi K, Rao S, McInnes IB, et al. Gout and incidence of 12 cardiovascular diseases: a case-control study including 152 663 individuals with gout and 709 981 matched controls. Lancet Rheumatol. 2024;6(3):e156–67.PubMedCrossRef
25.
Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med. 2004;350(11):1093–103.PubMedCrossRef
26.
Choi HK, De Vera MA, Krishnan E. Gout and the risk of type 2 diabetes among men with a high cardiovascular risk profile. Rheumatology (Oxford). 2008;47(10):1567–70.PubMedCrossRef
27.
Pan A, Teng GG, Yuan JM, Koh WP. Bidirectional association between self-reported hypertension and gout: the Singapore Chinese health study. PLoS One. 2015;10(10): e0141749.PubMedPubMedCentralCrossRef
28.
Clarson LE, Chandratre P, Hider SL, Belcher J, Heneghan C, Roddy E, et al. Increased cardiovascular mortality associated with gout: a systematic review and meta-analysis. Eur J Prev Cardiol. 2015;22(3):335–43.PubMedPubMedCentralCrossRef
29.
Perez-Ruiz F, Martinez-Indart L, Carmona L, Herrero-Beites AM, Pijoan JI, Krishnan E. Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout. Ann Rheum Dis. 2014;73(1):177–82.PubMedCrossRef
30.
Clarson LE, Hider SL, Belcher J, Heneghan C, Roddy E, Mallen CD. Increased risk of vascular disease associated with gout: a retrospective, matched cohort study in the UK clinical practice research datalink. Ann Rheum Dis. 2015;74(4):642–7.PubMedCrossRef
31.
Kuo CF, Grainge MJ, Mallen C, Zhang W, Doherty M. Comorbidities in patients with gout prior to and following diagnosis: case-control study. Ann Rheum Dis. 2016;75(1):210–7.PubMedCrossRef
32.
Choi HK, McCormick N, Yokose C. Excess comorbidities in gout: the causal paradigm and pleiotropic approaches to care. Nat Rev Rheumatol. 2022;18(2):97–111.PubMedCrossRef
33.
Borghi C, Agabiti-Rosei E, Johnson RJ, Kielstein JT, Lurbe E, Mancia G, et al. Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease. Eur J Intern Med. 2020;80:1–11.PubMedCrossRef
34.
Kim JY, Seo C, Pak H, Lim H, Chang TI. Uric acid and risk of cardiovascular disease and mortality: a longitudinal cohort study. J Korean Med Sci. 2023;38(38): e302.PubMedPubMedCentralCrossRef
35.
Kim SC, Liu J, Solomon DH. Risk of incident atrial fibrillation in gout: a cohort study. Ann Rheum Dis. 2016;75(8):1473–8.PubMedCrossRef
36.
Kim J, Lee SY, Lee J, Yoon S, Kim EG, Lee E, et al. Effects of uric acid on ischemic diseases, stratified by lipid levels: a drug-target, nonlinear Mendelian randomization study. Sci Rep. 2024;14(1):1338.PubMedPubMedCentralCrossRef
37.
Zhao G, Huang L, Song M, Song Y. Baseline serum uric acid level as a predictor of cardiovascular disease related mortality and all-cause mortality: a meta-analysis of prospective studies. Atherosclerosis. 2013;231(1):61–8.PubMedCrossRef
38.
Tamariz L, Hernandez F, Bush A, Palacio A, Hare JM. Association between serum uric acid and atrial fibrillation: a systematic review and meta-analysis. Heart Rhythm. 2014;11(7):1102–8.PubMedCrossRef
39.
Nozue T, Yamamoto S, Tohyama S, Fukui K, Umezawa S, Onishi Y, et al. Correlations between serum uric acid and coronary atherosclerosis before and during statin therapy. Coron Artery Dis. 2014;25(4):343–8.PubMedCrossRef
40.
Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA. Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthritis Rheum. 2009;61(7):885–92.PubMedPubMedCentralCrossRef
41.
Grayson PC, Kim SY, LaValley M, Choi HK. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2011;63(1):102–10.PubMedPubMedCentralCrossRef
42.
Cicero AF, Rosticci M, Fogacci F, Grandi E, D’Addato S, Borghi C, et al. High serum uric acid is associated to poorly controlled blood pressure and higher arterial stiffness in hypertensive subjects. Eur J Intern Med. 2017;37:38–42.PubMedCrossRef
43.
Viazzi F, Rebora P, Giussani M, Orlando A, Stella A, Antolini L, et al. Increased serum uric acid levels blunt the antihypertensive efficacy of lifestyle modifications in children at cardiovascular risk. Hypertension. 2016;67(5):934–40.PubMedCrossRef
44.
Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension. 2001;38(5):1101–6.PubMedCrossRef
45.
Mene P, Punzo G. Uric acid: bystander or culprit in hypertension and progressive renal disease? J Hypertens. 2008;26(11):2085–92.PubMedCrossRef
46.
Thottam GE, Krasnokutsky S, Pillinger MH. Gout and Metabolic Syndrome: a Tangled Web. Curr Rheumatol Rep. 2017;19(10):60.PubMedCrossRef
47.
Higgins P, Dawson J, Lees KR, McArthur K, Quinn TJ, Walters MR. Xanthine oxidase inhibition for the treatment of cardiovascular disease: a systematic review and meta-analysis. Cardiovasc Ther. 2012;30(4):217–26.PubMedCrossRef
48.
Scheepers LE, Wei FF, Stolarz-Skrzypek K, Malyutina S, Tikhonoff V, Thijs L, et al. Xanthine oxidase gene variants and their association with blood pressure and incident hypertension: a population study. J Hypertens. 2016;34(11):2147–54.PubMedCrossRef
49.
Scheepers L, Boonen A, Dagnelie PC, Schram MT, van der Kallen CJH, Henry RMA, et al. Uric acid and blood pressure: exploring the role of uric acid production in The Maastricht Study. J Hypertens. 2017;35(10):1968–75.PubMedCrossRef
50.
Scheepers LE, Boonen A, Pijnenburg W, Bierau J, Staessen JA, Stehouwer CD, et al. Associations of plasma uric acid and purine metabolites with blood pressure in children: the KOALA Birth Cohort Study. J Hypertens. 2017;35(5):982–93.PubMedCrossRef
51.
Lyngdoh T, Vuistiner P, Marques-Vidal P, Rousson V, Waeber G, Vollenweider P, et al. Serum uric acid and adiposity: deciphering causality using a bidirectional Mendelian randomization approach. PLoS One. 2012;7(6): e39321.PubMedPubMedCentralCrossRef
52.
Nitsch D, Molokhia M, Smeeth L, DeStavola BL, Whittaker JC, Leon DA. Limits to causal inference based on Mendelian randomization: a comparison with randomized controlled trials. Am J Epidemiol. 2006;163(5):397–403.PubMedCrossRef
53.
54.
McKeigue PM, Campbell H, Wild S, Vitart V, Hayward C, Rudan I, et al. Bayesian methods for instrumental variable analysis with genetic instruments ('Mendelian randomization’): example with urate transporter SLC2A9 as an instrumental variable for effect of urate levels on metabolic syndrome. Int J Epidemiol. 2010;39(3):907–18.PubMedPubMedCentralCrossRef
55.
McCormick N, O’Connor MJ, Yokose C, Merriman TR, Mount DB, Leong A, et al. Assessing the causal relationships between insulin resistance and hyperuricemia and gout using bidirectional mendelian randomization. Arthritis Rheumatol. 2021;73(11):2096–104.PubMedPubMedCentralCrossRef
56.
Yu X, Wang T, Huang S, Zeng P. Evaluation of the causal effects of blood lipid levels on gout with summary level GWAS data: two-sample Mendelian randomization and mediation analysis. J Hum Genet. 2021;66(5):465–73.PubMedCrossRef
57.
Rasheed H, Hughes K, Flynn TJ, Merriman TR. Mendelian randomization provides no evidence for a causal role of serum urate in increasing serum triglyceride levels. Circ Cardiovasc Genet. 2014;7(6):830–7.PubMedPubMedCentralCrossRef
58.
So AK, Martinon F. Inflammation in gout: mechanisms and therapeutic targets. Nat Rev Rheumatol. 2017;13(11):639–47.PubMedCrossRef
59.
Pascual E. Persistence of monosodium urate crystals and low-grade inflammation in the synovial fluid of patients with untreated gout. Arthritis Rheum. 1991;34(2):141–5.PubMedCrossRef
60.
Patetsios P, Song M, Shutze WP, Pappas C, Rodino W, Ramirez JA, et al. Identification of uric acid and xanthine oxidase in atherosclerotic plaque. Am J Cardiol. 2001;88(2):188–91 (A6).PubMedCrossRef
61.
Liu-Bryan R, Guo T, Lee J, Terkeltaub R. Atherogenic activation of human vascular smooth muscle cells by monosodium urate crystals. Gout Urate Cryst Depos Dis. 2023;1(3):192–207.CrossRef
62.
Pascart T, Carpentier P, Choi HK, Norberciak L, Ducoulombier V, Luraschi H, et al. Identification and characterization of peripheral vascular color-coded DECT lesions in gout and non-gout patients: the VASCURATE study. Semin Arthritis Rheum. 2021;51(4):895–902.PubMedCrossRef
63.
Barazani SH, Chi WW, Pyzik R, Chang H, Jacobi A, O’Donnell T, et al. Quantification of uric acid in vasculature of patients with gout using dual-energy computed tomography. World J Radiol. 2020;12(8):184–94.PubMedPubMedCentralCrossRef
64.
Dalbeth N, Alhilali M, Riordan P, Narang R, Chhana A, McGlashan S, et al. Vascular deposition of monosodium urate crystals in gout: analysis of cadaveric tissue by dual-energy computed tomography and compensated polarizing light microscopy. Arthritis Rheumatol. 2022;74(7):1295–6.PubMedCrossRef
65.
Andres M, Mendieta L, Argente-Del-Castillo E, Trigueros M, Minano A, Pascual E. Birefringent crystals deposition and inflammasome expression in human atheroma plaques by levels of uricemia. Joint Bone Spine. 2022;89(5): 105423.PubMedCrossRef
66.
Pascart T, Budzik JF. Does monosodium urate crystal vascular deposition exist? Review of the evidence. Gout Urate Cryst Depos Dis. 2023;1(3):208–16.CrossRef
67.
Pascart T, Latourte A, Flipo RM, Chales G, Coblentz-Baumann L, Cohen-Solal A, et al. 2020 recommendations from the French Society of Rheumatology for the management of gout: urate-lowering therapy. Joint Bone Spine. 2020;87(5):395–404.PubMedCrossRef
68.
Hui M, Carr A, Cameron S, Davenport G, Doherty M, Forrester H, et al. The British society for rheumatology guideline for the management of gout. Rheumatology (Oxford). 2017;56(7):1246.PubMedCrossRef
69.
Group Sw, collaboration ESCCr. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021;42(25):2439–54.CrossRef
70.
Arts EE, Popa CD, Den Broeder AA, Donders R, Sandoo A, Toms T, et al. Prediction of cardiovascular risk in rheumatoid arthritis: performance of original and adapted SCORE algorithms. Ann Rheum Dis. 2016;75(4):674–80.PubMedCrossRef
71.
Solomon DH, Greenberg J, Curtis JR, Liu M, Farkouh ME, Tsao P, et al. Derivation and internal validation of an expanded cardiovascular risk prediction score for rheumatoid arthritis: a Consortium of Rheumatology Researchers of North America Registry Study. Arthritis Rheumatol. 2015;67(8):1995–2003.PubMedCrossRef
72.
Andres M, Bernal JA, Sivera F, Quilis N, Carmona L, Vela P, et al. Cardiovascular risk of patients with gout seen at rheumatology clinics following a structured assessment. Ann Rheum Dis. 2017;76(7):1263–8.PubMedCrossRef
73.
Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–88.PubMedCrossRef
74.
Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;74(10):e177–232.PubMedPubMedCentralCrossRef
75.
Chen JH, Lan JL, Cheng CF, Liang WM, Lin HY, Tsay GJ, et al. Effect of urate-lowering therapy on all-cause and cardiovascular mortality in hyperuricemic patients without gout: a case-matched cohort study. PLoS One. 2015;10(12): e0145193.PubMedPubMedCentralCrossRef
76.
Yen FS, Hsu CC, Li HL, Wei JC, Hwu CM. Urate-lowering therapy may mitigate the risks of hospitalized stroke and mortality in patients with gout. PLoS One. 2020;15(6): e0234909.PubMedPubMedCentralCrossRef
77.
Dubreuil M, Zhu Y, Zhang Y, Seeger JD, Lu N, Rho YH, et al. Allopurinol initiation and all-cause mortality in the general population. Ann Rheum Dis. 2015;74(7):1368–72.PubMedCrossRef
78.
Wei L, Mackenzie IS, Chen Y, Struthers AD, MacDonald TM. Impact of allopurinol use on urate concentration and cardiovascular outcome. Br J Clin Pharmacol. 2011;71(4):600–7.PubMedPubMedCentralCrossRef
79.
Grimaldi-Bensouda L, Alperovitch A, Aubrun E, Danchin N, Rossignol M, Abenhaim L, et al. Impact of allopurinol on risk of myocardial infarction. Ann Rheum Dis. 2015;74(5):836–42.PubMedCrossRef
80.
Singh JA, Ramachandaran R, Yu S, Curtis JR. Allopurinol use and the risk of acute cardiovascular events in patients with gout and diabetes. BMC Cardiovasc Disord. 2017;17(1):76.PubMedPubMedCentralCrossRef
81.
Kok VC, Horng JT, Chang WS, Hong YF, Chang TH. Allopurinol therapy in gout patients does not associate with beneficial cardiovascular outcomes: a population-based matched-cohort study. PLoS ONE. 2014;9(6): e99102.PubMedPubMedCentralCrossRef
82.
Kim SC, Schneeweiss S, Choudhry N, Liu J, Glynn RJ, Solomon DH. Effects of xanthine oxidase inhibitors on cardiovascular disease in patients with gout: a cohort study. Am J Med. 2015;128(6):653 (e7- e16).PubMedCentralCrossRef
83.
84.
Mackenzie IS, Hawkey CJ, Ford I, Greenlaw N, Pigazzani F, Rogers A, et al. Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial. Lancet. 2022;400(10359):1195–205.PubMedCrossRef
85.
Perez Ruiz F, Richette P, Stack AG, Karra Gurunath R, Garcia de Yebenes MJ, Carmona L. Failure to reach uric acid target of <0.36 mmol/L in hyperuricaemia of gout is associated with elevated total and cardiovascular mortality. RMD Open. 2019;5(2): e001015.PubMedPubMedCentralCrossRef
86.
Schumacher HR Jr, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008;59(11):1540–8.PubMedCrossRef
87.
Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353(23):2450–61.PubMedCrossRef
88.
Becker MA, Schumacher HR, Espinoza LR, Wells AF, MacDonald P, Lloyd E, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010;12(2):R63.PubMedPubMedCentralCrossRef
89.
White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A, et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med. 2018;378(13):1200–10.PubMedCrossRef
90.
Mackenzie IS, Ford I, Nuki G, Hallas J, Hawkey CJ, Webster J, et al. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet. 2020;396(10264):1745–57.PubMedCrossRef
91.
92.
Libby P, Buring JE, Badimon L, Hansson GK, Deanfield J, Bittencourt MS, et al. Atherosclerosis. Nat Rev Dis Primers. 2019;5(1):56.PubMedCrossRef
93.
Latourte A, Pascart T, Flipo RM, Chales G, Coblentz-Baumann L, Cohen-Solal A, et al. 2020 Recommendations from the french society of rheumatology for the management of gout: management of acute flares. Joint Bone Spine. 2020;87(5):387–93.PubMedCrossRef
94.
Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381(26):2497–505.PubMedCrossRef
95.
Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, et al. Colchicine in patients with chronic coronary disease. N Engl J Med. 2020;383(19):1838–47.PubMedCrossRef
96.
Kommu S, Arepally S. The effect of colchicine on atrial fibrillation: a systematic review and meta-analysis. Cureus. 2023;15(2): e35120.PubMedPubMedCentral
97.
Lopez J, Borzak S. In noncardiac thoracic surgery, low-dose colchicine did not reduce AF or myocardial injury after noncardiac surgery at 14 d. Ann Intern Med. 2024;177(1):JC3.PubMedCrossRef
98.
Crittenden DB, Lehmann RA, Schneck L, Keenan RT, Shah B, Greenberg JD, et al. Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout. J Rheumatol. 2012;39(7):1458–64.PubMedPubMedCentralCrossRef
99.
Solomon DH, Liu CC, Kuo IH, Zak A, Kim SC. Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: a cohort study using electronic medical records linked with Medicare claims. Ann Rheum Dis. 2016;75(9):1674–9.PubMedCrossRef
100.
Shah B, Toprover M, Crittenden DB, Jeurling S, Pike VC, Krasnokutsky S, et al. Colchicine use and incident coronary artery disease in male patients with Gout. Can J Cardiol. 2020;36(11):1722–8.PubMedCrossRef
101.
Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119–31.PubMedCrossRef
102.
Schjerning AM, McGettigan P, Gislason G. Cardiovascular effects and safety of (non-aspirin) NSAIDs. Nat Rev Cardiol. 2020;17(9):574–84.PubMedCrossRef
103.
Stamp LK, Chapman PT. Gout and its comorbidities: implications for therapy. Rheumatology (Oxford). 2013;52(1):34–44.PubMedCrossRef
104.
Loustau C, Rosine N, Forien M, Ottaviani S, Juge PA, Liote F, et al. Effectiveness and safety of anakinra in gout patients with stage 4–5 chronic kidney disease or kidney transplantation: a multicentre, retrospective study. Joint Bone Spine. 2018;85(6):755–60.PubMedCrossRef
105.
Ottaviani S, Molto A, Ea HK, Neveu S, Gill G, Brunier L, et al. Efficacy of anakinra in gouty arthritis: a retrospective study of 40 cases. Arthritis Res Ther. 2013;15(5):R123.PubMedPubMedCentralCrossRef
106.
Schlesinger N. Difficult-to-treat gouty arthritis: a disease warranting better management. Drugs. 2011;71(11):1413–39.PubMedCrossRef
107.
Schlesinger N, Alten RE, Bardin T, Schumacher HR, Bloch M, Gimona A, et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis. 2012;71(11):1839–48.PubMedCrossRef
108.
109.
Yu TF, Gutman AB. Study of the paradoxical effects of salicylate in low, intermediate and high dosage on the renal mechanisms for excretion of urate in man. J Clin Invest. 1959;38(8):1298–315.PubMedPubMedCentralCrossRef
110.
Hueskes BA, Roovers EA, Mantel-Teeuwisse AK, Janssens HJ, van de Lisdonk EH, Janssen M. Use of diuretics and the risk of gouty arthritis: a systematic review. Semin Arthritis Rheum. 2012;41(6):879–89.PubMedCrossRef
111.
Choi HK, Soriano LC, Zhang Y, Rodriguez LA. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. BMJ. 2012;12(344): d8190.CrossRef
112.
Miao Y, Ottenbros SA, Laverman GD, Brenner BM, Cooper ME, Parving HH, et al. Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial. Hypertension. 2011;58(1):2–7.PubMedCrossRef
113.
Ka T, Inokuchi T, Tsutsumi Z, Takahashi S, Moriwaki Y, Yamamoto T. Effects of a fenofibrate/losartan combination on the plasma concentration and urinary excretion of purine bases. Int J Clin Pharmacol Ther. 2006;44(1):22–6.PubMedCrossRef
114.
Takahashi S, Moriwaki Y, Yamamoto T, Tsutsumi Z, Ka T, Fukuchi M. Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism. Ann Rheum Dis. 2003;62(6):572–5.PubMedPubMedCentralCrossRef
115.
Yamamoto T, Moriwaki Y, Takahashi S, Tsutsumi Z, Hada T. Effect of fenofibrate on plasma concentration and urinary excretion of purine bases and oxypurinol. J Rheumatol. 2001;28(10):2294–7.PubMed
116.
Derosa G, Maffioli P, Sahebkar A. Plasma uric acid concentrations are reduced by fenofibrate: a systematic review and meta-analysis of randomized placebo-controlled trials. Pharmacol Res. 2015;102:63–70.PubMedCrossRef
117.
Derosa G, Maffioli P, Reiner Z, Simental-Mendia LE, Sahebkar A. Impact of statin therapy on plasma uric acid concentrations: a systematic review and meta-analysis. Drugs. 2016;76(9):947–56.PubMedCrossRef
118.
Wu JH, Foote C, Blomster J, Toyama T, Perkovic V, Sundstrom J, et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2016;4(5):411–9.PubMedCrossRef
119.
Kluger AY, Tecson KM, Lee AY, Lerma EV, Rangaswami J, Lepor NE, et al. Class effects of SGLT2 inhibitors on cardiorenal outcomes. Cardiovasc Diabetol. 2019;18(1):99.PubMedPubMedCentralCrossRef
120.
Fralick M, Chen SK, Patorno E, Kim SC. Assessing the risk for gout with sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: a population-based cohort study. Ann Intern Med. 2020;172(3):186–94.PubMedPubMedCentralCrossRef
121.
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.PubMedCrossRef
122.
Zhao SS, Rajasundaram S, Karhunen V, Alam U, Gill D. Sodium-glucose cotransporter 1 inhibition and gout: mendelian randomisation study. Semin Arthritis Rheum. 2022;56: 152058.PubMedCrossRef
123.
Zhao Y, Xu L, Tian D, Xia P, Zheng H, Wang L, et al. Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: a meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2018;20(2):458–62.PubMedCrossRef
124.
Banerjee M, Pal R, Mukhopadhyay S. Can SGLT2 inhibitors prevent incident gout? A systematic review and meta-analysis. Acta Diabetol. 2022;59(6):783–91.PubMedCrossRef
125.
Zhou J, Liu X, Chou OH, Li L, Lee S, Wong WT, et al. Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes. Rheumatology (Oxford). 2023;62(4):1501–10.PubMedCrossRef
126.
Yokose C, McCormick N, Abhishek A, Dalbeth N, Pascart T, Liote F, et al. The clinical benefits of sodium-glucose cotransporter type 2 inhibitors in people with gout. Nat Rev Rheumatol. 2024;20(4):216–31.PubMedCrossRef
127.
McCormick N, Yokose C, Wei J, Lu N, Wexler DJ, Avina-Zubieta JA, et al. Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for recurrent gout flares and gout-primary emergency department visits and hospitalizations : a general population cohort study. Ann Intern Med. 2023;176(8):1067–80.PubMedCrossRef
128.
American Diabetes A. Standards of care in diabetes-2023 abridged for primary care providers. Clin Diabetes. 2022;41(1):4–31.CrossRef
Metadata
Title
Managing Gout in Patients with Metabolic Syndrome
Authors
Esther Ebstein
Sébastien Ottaviani
Publication date
27-07-2024
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 8/2024
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.1007/s40266-024-01132-x

Other articles of this Issue 8/2024

Drugs & Aging 8/2024 Go to the issue

Review Article

Prescribing Appropriate Medicines to Older Adults: A Finnish Experience with the Web-Based Meds75+ Database

Original Research Article

Real-World Drug Survival of Biologics and Targeted Synthetic Disease-Modifying Anti-rheumatic Drugs Among Patients with Psoriatic Arthritis

Original Research Article

Development of a Predictive Model for Potentially Inappropriate Medications in Older Patients with Cardiovascular Disease

Current Opinion

Low-Dose Glucocorticoids in Older Patients with Rheumatoid Arthritis: What Does the Evidence Say?

Current Opinion

Pre-clinical Models for Geriatric Pharmacotherapy
Image Credits